| Acronym | Study Title | Ethics Reference | Principle Investigator |
Trial Co-ordinator |
Study Status |
|---|---|---|---|---|---|
| ACUTE LYMPHOBLASTIC LEUKAEMIA | |||||
|
(Dasatinib for Ph+ ALL) |
A PHASE II STUDY OF DASATINIB COMBINED WITH INDUCTION CHEMOTHERAPY IN PREVIOUSLY UNTREATED DE NOVO PHILADELPHIA + ACUTE LYMPHOBLASTIC LEUKAEMIA | Dr Andrew Butler | Jo Sanders | open to accrual | |
| ACUTE MYELOID LEUKAEMIA | |||||
|
(Relapsed or Refractory AML) |
AN OPEN LABEL RANDOMIZED CONTROLLED PHASE II STUDY OF
AS1411 COMBINED WITH CYTARABINE IN THE TREATMENT OF PATIENTS WITH
PRIMARY REFRACTORY OR RELAPSED ACUTE MYELOID LEUKAEMIA. PROTOCOL NUMBER: AS1411-C-203 |
Dr Ruth Spearing | Jo Sanders | open to accrual | |
|
|
allo stem cell transplantation with reduced conditioning
(RICT) versus best standard of care in AML in first complete remission. PROTOCOL NUMBER: TRALG1/02 |
URB/ 06/06/043 |
Dr Ruth Spearing | Jo Sanders | open to accrual |
| CHRONIC LYMPHOCYTIC LEUKAEMIA | |||||
|
(Lenalidomide for CLL maintenance) |
A PHASE 3, MULTICENTRE RANDOMISED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF
LENALIDOMIDE (REVLIMID) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL
CLL FOLLOWING SECOND-LINE THERAPY. PROTOCOL NUMBER: CC-5013-CLL-002 |
Dr Steve Gibbons | Jo Sanders | open to accrual | |
|
|
A RANDOMIZED, OPEN-LABEL MULTICENTRE, PHASE2/3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUMILIXIMAB IN COMBINATION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB ALONE IN SUBJECTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA. | Dr Peter Ganly | Jo Sanders | open to accrual | |
| CHRONIC MYELOID LEUKAEMIA | |||||
|
(CML9) |
A PHASE II STUDY IN ADULT PATIENTS WITH NEWLY
DIAGNOSED CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA OF INITIAL INTENSIFIED
IMATINIB THERAPY AND SEQUENTIAL DOSE-ESCALATION FOLLOWED BY TREATMENT
WITH NILOTINIB IN SUBOPTIMAL RESPONDERS TO DETERMINE THE RATE OF
DURATION OF MAJOR MOLECULAR RESPONSE. PROTOCOL NUMBER: CML9 |
MEC/ 07/10/132 |
Dr Andrew Butler | Jo Sanders | suspended recruitment |
| MULTIPLE MYELOMA | |||||
|
(First line therapy MPT v Len/Dex) |
A PHASE III, RANDOMISED, OPEN-LABEL, 3-ARM STUDY TO
DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS
LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18
4-WEEK CYCLES VERSUS THE COMBINATION OF MELPHALAN, PREDNISONE AND
THALIDOMIDE GIVEN FOR 12 6-WEEK CYCLES IN PATIENTS WITH PREVIOUSLY
UNTREATED MULTIPLE MYELOMA WHO ARE EITHER 65 YEARS OF AGE OR OLDER OR
NOT CANDIDATES FOR STEM CELL TRANSPLANTATION. PROTOCOL NUMBER: IFM07-01 |
Dr Liam Fernyhough | Jo Sanders | open to accrual | |
|
(Relapsed Myeloma Study) |
A PHASE II TRIAL OF LOW DOSE LENALIDOMIDE AND
DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PATIENTS AT
HIGH RISK FOR MYELOSUPPRESSION. PROTOCOL NUMBER: RV-PL-0103 |
Dr Liam Fernyhough | Jo Sanders | open to accrual | |
|
(Relapsed Valcade + Vorinostat) |
An International, Multicenter, Randomized, Double-Blind,
Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib
in Patients with Multiple Myeloma. PROTOCOL NUMBER: MK-0683-088 |
Dr Peter Ganly | Jo Sanders | open to accrual | |
|
NON-HODGKIN'S LYMPHOMA |
|||||
|
(DLBC-Main Study) |
A MULTI-CENTRE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III
TRIAL COMPARING THE EFFICACY OF BEVACIZUMAB IN COMBINATION WITH
RITUXIMAB AND CHOP (RA-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN
PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL
LYMPHOMA. PROTOCOL NUMBER: B0200603. |
MEC/ 07/04/049 |
Dr Peter Ganly |
Jo Sanders | open to accrual |
|
(Indolent NHL) |
AN OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP STUDY OF
BENDAMUSTINE HYDROCHLORIDE AND RITUXIMAB (BR) COMPARED WITH RITUXIMAB,
CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE (R-CVP) OR RITUXIMAB,
CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (R-CHOP) IN
THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED INDOLENT
NON-HODGKIN'S LYMPHOMA (NHL) OR MANTLE CELL LYMPHOMA (MCL). PROTOCOL NUMBER: C18083/3064/NL/MN |
Dr Peter Ganly |
Jo Sanders | open to accrual | |
| PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | |||||
|
|
OBSERVATIONAL REGISTRY COMPILING DATA ON THE HISTORY AND MANAGEMENT OF PATIENTS DIAGNOSED WITH PNH |
URA/ 06/02/001 |
Dr Ruth Spearing | Jo Sanders | open to accrual |
| PRIMARY THROMBOCYTHAEMIA | |||||
|
|
A RANDOMISED TRIAL TO COMPARE ASPIRIN VERSUS HYDROXYUREA/ASPIRIN
IN 'INTERMEDIATE RISK' PT AND ASPIRIN ONLY WITH OBSERVATION IN 'LOW
RISK' PT PROTOCOL NUMBER: PT1 |
00/11/157 | Dr Steve Gibbons | Jo Sanders | open to accrual |
| TRANSPLANT (SUPPORTIVE CARE) | |||||
|
(Post Allo SCT) |
A TREATMENT ALGORITHM EVALUATING THE EFFECT OF ZOLEDRONIC ACID ON BONE MINERAL DENSITY LOSS AFTER ALLOGENIC STEM CELL TRANSPLANTATION. | MEC/09/02/010 | Dr Peter Ganly | Jo Sanders | open to accrual |